Oncologic and surgical outcomes of endoscopic therapy compared to surgical treatment of upper tract urothelial carcinoma stratified by tumor grade
An analysis of the national cancer database
DOI:
https://doi.org/10.5489/cuaj.9654Keywords:
endoscopic, Nephroureterectomy, distal ureterectomyAbstract
Introduction: Oncologic outcomes of endoscopic treatment (ET) vs. extirpative surgery (ES=radical nephroureterectomy/segmental ureterectomy [RNU, SU]) for upper tract urothelial carcinoma (UTUC) are not well-defined. We queried the National Cancer Database to compare the overall survival (OS) and surgical outcomes of ET to ES for localized UTUC stratified by grade.
Methods: We conducted a retrospective cohort study including patients 18−90 years old, diagnosed with localized UTUC from 2004−2021. The primary outcome was OS. Secondary outcomes included the surgical outcomes of postoperative mortality, length of hospital stay, and 30-day readmission rate. We conducted 1:1 propensity-score matching (PSM). Survival analysis by accelerated failure time model with Weibull distribution with clustering (reporting time ratio [TR] and 95% confidence interval [CI]) was conducted. Mann-Whitney test or Fisher’s exact test were used to compare other outcomes.
Results: ET was used to treat 3.6% of UTUC cases in 2004 to 9.8% in 2020. After all inclusion and exclusion, there were 32 205 patients: 1747 (5.42%) in the ET arm and 30458 (94.58%) in the ES arm. After PSM, 1541 patients were included in each cohort. For high-grade UTUC, ET vs. ES was associated with reduced OS (TR: 0.51, 95% CI 0.39−0.65). For low-grade UTUC, ET vs. ES was not associated with diminished OS (TR 0.88, 95% CI 0.72−1.07).
Conclusions: In appropriately selected patients with low-grade UTUC, ET appears to confer comparable survival outcomes to extirpative approaches; however, in those with high-grade UTUC, we found lower OS among those managed with ET. This may be from poorer cancer control or may reflect residual confounding among those patients selected for ET (e.g., greater comorbidity or conditions precluding ES).
Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.
